Meningitis, Meningococcal: Clinical Trials

13 trials for Meningitis, Meningococcal, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 13 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 8, Unknown 3, Not yet recruiting 1, Recruiting 1
Phase 23Completed 2, Unknown 1

Follow Meningitis, Meningococcal: new trials by email Literature Review of Meningitis, Meningococcal trials Research Report on Meningitis, Meningococcal

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine
high-dose Group ACYW135X Meningococcal Conjugate Vaccine, medium-dose Group ACYW135X Meningococcal Conjugate Vaccine, low-dose Group ACYW135X Meningococcal Conjugate Vaccine - Meningococcal Meningitis
Phase 1Not yet recruitingSinovac Life Sciences Co., Ltd.1502026-01-212026-01-28
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP) - Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis
Phase 1RecruitingCanSino Biologics Inc.2602025-12-192025-12-31
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.
Meningococcal Group ACYW135 Conjugate Vaccine - Meningococcal Infections
Phase 1CompletedWalvax Biotechnology Co., Ltd.1002018-07-172020-01-22
Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age
Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free), Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant) - Meningitis, Meningococcal Meningitis
Phase 1 / Phase 2UnknownBeijing Zhifei Lvzhu Biopharmaceutical Co., Ltd3602016-08-012016-09-29
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
Meningococcal ACYW135 Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal
Phase 1UnknownBeijing Zhifei Lvzhu Biopharmaceutical Co., Ltd2002016-06-012016-08-26
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine
freeze-dried group ACYW135 MCV - Meningococcal Meningitis
Phase 1UnknownLanzhou Institute of Biological Products Co., Ltd2002015-06-012015-06-25
Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos
'MenCC-Bio', MENJUGATE - Meningitis, Meningococcal, Serogroup C
Phase 1CompletedThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)602014-05-012015-09-16
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
meningococcal meningitis conjugate vaccine, quadrivalent - Meningococcal Meningitis, Meningococcal Infections
Phase 1CompletedJN-International Medical Corporation602011-11-012013-01-14
Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults
rLP2086 vaccine or control - Meningitis, Meningococcal
Phase 1CompletedPfizer482009-04-012015-08-06
Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults
meningococcal B rLP2086 vaccine candidate, Blood draw - Meningitis, Meningococcal
Phase 1 / Phase 2CompletedWyeth is now a wholly owned subsidiary of Pfizer602008-10-012011-08-23
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate - Meningococcal Infections, Meningococcal Meningitis
Phase 1 / Phase 2CompletedSanofi Pasteur, a Sanofi Company2162007-10-012013-09-20
Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
MnB rLP2086 - Meningitis, Meningococcal
Phase 1CompletedWyeth is now a wholly owned subsidiary of Pfizer1082006-03-012007-12-05
Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.
25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine, 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine - Meningitis, Meningococcal, Serogroup B
Phase 1CompletedU.S. Army Medical Research and Development Command342005-12-052018-10-29

Narrower conditions

Meningococcal Infections (4)  ·  Meningitis (2)  ·  Central Nervous System Infections (1)  ·  Diphtheria (1)  ·  Haemophilus Infections (1)  ·  Tetanus (1)

Broader conditions

Bacterial Infections (13)  ·  Bacterial Infections and Mycoses (13)  ·  Central Nervous System Bacterial Infections (13)  ·  Central Nervous System Diseases (13)  ·  Gram-Negative Bacterial Infections (13)  ·  Infections (13)  ·  Meningitis, Bacterial (13)  ·  Neisseriaceae Infections (13)  ·  Nervous System Diseases (13)  ·  Neuroinflammatory Diseases (13)  ·  Central Nervous System Infections (12)  ·  Meningitis (11)  ·  Meningococcal Infections (9)  ·  Actinomycetales Infections (1)  ·  Clostridium Infections (1)

Interventions

Blood Specimen Collection (1)  ·  CRM197 (non-toxic variant of diphtheria toxin) (1)  ·  HibTITER protein, Haemophilus influenzae (1)  ·  Meningococcal Vaccines (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  Vaccines, Combined (1)

Sponsors

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (2)  ·  CanSino Biologics Inc. (1)  ·  JN-International Medical Corporation (1)  ·  Lanzhou Institute of Biological Products Co., Ltd (1)  ·  Pfizer (1)  ·  Sanofi Pasteur, a Sanofi Company (1)  ·  Sinovac Life Sciences Co., Ltd. (1)  ·  The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1)  ·  U.S. Army Medical Research and Development Command (1)  ·  Walvax Biotechnology Co., Ltd. (1)

Countries

China (5)  ·  United States (4)  ·  Australia (2)  ·  Brazil (1)

Top investigators

Barnett Gibbs, MD (1)  ·  Paul B Keiser (1)  ·  Sudesh Nagavalli, MD (1)  ·  Yanxia Wang (1)

Results publications

PMID 35164991, PMID 22832260, PMID 23352429